The inaugural COTC trial evaluated a tumor vasculature targeted adeno-associated virus phage vector targeted to alphaV integrins expressed on tumor endothelium and delivering tumor necrosis factor (TNF), in preparation for human trials. This evidence concerns the gene TNF and neoplasm.